Molecular imaging of neuroendocrine tumors optimizes radiotherapy dose

(Society of Nuclear Medicine) Aggressive neuroendocrine cancer is something of a dark horse -- a rare, elusive and persevering force linked to discouraging long-term survival rates. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are presenting a molecular imaging technique that allows oncologists to set patients' radiotherapy doses right at that critical limit of delivering the most powerful kill to neuroendocrine tumors (NETs) while prote...